About us
REPLICor is a biopharmaceutical company developing a new antiviral drug that will revolutionize the treatment of patients with chronic hepatitis B and for patients with chronic hepatitis C undergoing liver transplantation. This antiviral drug is currently being tested in a clinical trial in Asia to demonstrate its safety and activity in human patients. It is expected that our drug will also find important applications in the treatment of patients infected with chronic hepatitis C, influenza, RSV and CMV.
Development Pipeline
|
VIRUS |
INDICATION |
DEVELOPMENT |
|
HBV |
Therapy for chronic HBV |
Phase I / II |
|
HCV |
Therapy for chronic HCV |
Phase I |
|
HCV |
Prophylaxis for liver transplantation in HCV positive patients |
Phase I |
|
Influenza |
Therapy for newly emergent influenza strains |
Preclinical |
|
RSV |
Therapy for respiratory disease |
Preclinical |
|
CMV |
Prophylaxis and therapy in immunocompromised patients |
Preclinical |
|
CMV |
Prophylaxis for perinatal transmission |
Preclinical |